• Flanders Investment & Trade
  • Team Vesalius

Gil Beyen is the CEO of Erytech Pharma, a clinical-stage biopharmaceutical company which develops innovative therapies for rare cancers and orphan diseases.

Gil Beyen


flanders.bio & Bio.be

Board member

Prior to that, he was the head of TiGenix, a biotech company he co-founded. Combining degrees in bioengineering and business development, Beyen was once partner and chief of the life sciences division of Arthur D. Little, an international management consulting firm in Brussels. He serves on the board of life sciences cluster organization flanders.bio and biotech federation Bio.be.

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?